ReCor Medical adds another $12m for trial of Paradise renal denervation device

ReCor Medical last week added a $12 million contribution from Otsuka Pharmaceutical (TYO:4578) to the $10 million it raised from the Japanese conglomerate last year for a clinical trial of its Paradise renal denervation device for treating hypertension, ReCor president & CEO Andrew Weiss told MassDevice.com this morning. In May 2016 Otsuka participated in a strategic investment of an unspecified amount; Weiss told us that that round and the $12 million debt financing added last week are earmarked for the Radiance-HTN efficacy study of the Paradise device, which is designed to use ultrasound waves rather than radiofrequency ablation of nerves lining the renal artery to treat high blood pressure. ReCor won an investigational device exemption from the FDA in February 2016 for the Radiance-HTN study, which launched in April of that year. The sham-controlled trial consists of two 60-day arms, he said: One, the “Solo” cohort, evaluating the Paradise treatment in patients with moderate hypertension who take one or two drugs for it, and a second called “Trio” investigating the treatment in patients with resistant hypertension who take three or more medications. Weiss said the study design calls for the Solo cohort to stop taking blood pressure medications for a month before being randomized to either Paradise or a sham procedure. The Trio group are taken off of their anti-hypertensive cocktail, stabilized for a month and then given the three-drug Ex...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Funding Roundup Wall Street Beat Hypertension ReCor Medical Source Type: news